NUVB.US Nuvation Bio Inc

Healthcare Biotechnology USA Stocks
4.00 USD
Close of Nov 15, 2026
3.82 9.75
Market cap
USD 1.41B
P/E
-
P/B
6.18x
ROE
-58.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NUVB.US undervalued?

Graham number

The Graham number of Nuvation Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nuvation Bio Inc fundamental analysis

No fundamental analysis for Nuvation Bio Inc yet.

Nuvation Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nuvation Bio Inc

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safu…

Full company profile